Search Results

There are 26305 results for: content related to: The effects of auditory startle and nonstartle stimuli on step initiation in Parkinson's disease

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  3. You have full text access to this OnlineOpen article
    Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome

    Annals of the New York Academy of Sciences

    Volume 1329, Issue 1, November 2014, Pages: 45–66, Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran and Mahnaz Asgharnejad

    Version of Record online : 21 AUG 2014, DOI: 10.1111/nyas.12508

  4. You have free access to this content
    Poster Session

    Movement Disorders

    Volume 31, Issue S2, June 2016, Pages: S1–S697,

    Version of Record online : 19 JUN 2016, DOI: 10.1002/mds.26688

  5. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  6. Lack of Pharmacokinetic Interactions Between Transdermal Rotigotine and Oral Levodopa/Carbidopa

    The Journal of Clinical Pharmacology

    Volume 49, Issue 9, September 2009, Pages: 1047–1055, Marina Braun, Willi Cawello, Jens-Otto Andreas, Dipl Math, Hilmar Boekens and Rolf Horstmann

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009338481

  7. Rotigotine transdermal patch for the treatment of Parkinson’s Disease

    Fundamental & Clinical Pharmacology

    Volume 27, Issue 1, February 2013, Pages: 81–95, Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti and Olivier Rascol

    Version of Record online : 9 FEB 2012, DOI: 10.1111/j.1472-8206.2012.01028.x

  8. Transdermal Rotigotine: A Clinically Innovative Dopamine-Receptor Agonist for the Management of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 12, December 2009, Pages: 1452–1467, Dr. Jack J. Chen, Dr. David M. Swope, Dr. Khashayar Dashtipour and Dr. Kelly E. Lyons

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.29.12.1452

  9. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  10. Dopamine agonists for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 MAR 2011, DOI: 10.1002/14651858.CD006009.pub2

  11. You have free access to this content
    Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors

    British Journal of Pharmacology

    Volume 172, Issue 4, February 2015, Pages: 1124–1135, Martyn Wood, Vanessa Dubois, Dieter Scheller and Michel Gillard

    Version of Record online : 13 JAN 2015, DOI: 10.1111/bph.12988

  12. You have free access to this content
    Abstracts of The Movement Disorder Society's Eleventh International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 22, Issue S16, 2007, Pages: S1–S325,

    Version of Record online : 24 APR 2007, DOI: 10.1002/mds.21535

  13. Rotigotine improves restless legs syndrome: A 6-month randomized, double-blind, placebo-controlled trial in the United States

    Movement Disorders

    Volume 25, Issue 11, 15 August 2010, Pages: 1675–1683, Wayne A. Hening, Richard P. Allen, William G. Ondo, Arthur S. Walters, John W. Winkelman, Philip Becker, Richard Bogan, June M. Fry, David B. Kudrow, Kurt W. Lesh, Andreas Fichtner and Erwin Schollmayer

    Version of Record online : 13 JUL 2010, DOI: 10.1002/mds.23157

  14. You have full text access to this OnlineOpen article
    Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis

    European Journal of Neurology

    Volume 23, Issue 10, October 2016, Pages: 1556–1565, A. Antonini, K. R. Chaudhuri, B. Boroojerdi, M. Asgharnejad, L. Bauer, F. Grieger and D. Weintraub

    Version of Record online : 18 JUL 2016, DOI: 10.1111/ene.13078

  15. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial

    European Journal of Neurology

    Volume 22, Issue 10, October 2015, Pages: 1400–1407, A. Antonini, L. Bauer, E. Dohin, W. H. Oertel, O. Rascol, H. Reichmann, M. Schmid, P. Singh, E. Tolosa and K. Ray Chaudhuri

    Version of Record online : 22 JUN 2015, DOI: 10.1111/ene.12757

  16. You have free access to this content
    Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive

    British Journal of Clinical Pharmacology

    Volume 68, Issue 3, September 2009, Pages: 386–394, Marina Braun, Jan-Peer Elshoff, Jens-Otto Andreas, Louise Ischen Müller and Rolf Horstmann

    Version of Record online : 26 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03468.x

  17. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease–Associated Chronic Pain

    The Journal of Clinical Pharmacology

    Volume 56, Issue 7, July 2016, Pages: 852–861, Olivier Rascol, Theresa Zesiewicz, K. Ray Chaudhuri, Mahnaz Asgharnejad, Erwin Surmann, Elisabeth Dohin, Sigrid Nilius and Lars Bauer

    Version of Record online : 31 DEC 2015, DOI: 10.1002/jcph.678

  18. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Version of Record online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  19. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

    Clinical Pharmacology in Drug Development

    Volume 3, Issue 3, May/June 2014, Pages: 187–193, Jan-Peer Elshoff, Willi Cawello, Jens-Otto Andreas and Marina Braun

    Version of Record online : 12 FEB 2014, DOI: 10.1002/cpdd.78

  20. Thorough QT/QTc Study in Patients With Advanced Parkinson's Disease: Cardiac Safety of Rotigotine

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 5, November 2008, Pages: 595–603, M Malik, J-O Andreas, K Hnatkova, J Hoeckendorff, W Cawello, M Middle, R Horstmann and M Braun

    Version of Record online : 23 JUL 2008, DOI: 10.1038/clpt.2008.143